Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | CD38 | P28907 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16184225 | 0.92 | LIMK1 (0.35) | NPC1PKMRAB9AMAT2ATNF | |
| SCHEMBL16184213 | 0.91 | KIT (0.38) | KITJAK2CD38LIMK1LIMK2 | |
| SCHEMBL16184204 | 0.91 | SYK (0.43) | KITCDK2LIMK1LIMK2LMNA | |
| SCHEMBL14474183 | 0.91 | KIT (0.39) | KITPIK3CACD38CHRNA7LMNA | |
| SCHEMBL16184217 | 0.90 | PDGFRB (0.39) | NPC1PKMRAB9APIK3CAPIK3CB | |
| SCHEMBL16184203 | 0.90 | CYP1A2 (0.42) | NPC1KITMEN1KMT2ALMNA | |
| SCHEMBL16184228 | 0.89 | LIMK1 (0.39) | NPC1PKMRAB9AMAT2ATNF | |
| SCHEMBL16184207 | 0.89 | MAP4K4 (0.43) | NPC1MAT2ATNFROCK2MEN1 | |
| SCHEMBL16184224 | 0.88 | LIMK1 (0.38) | NPC1PKMRAB9AMAT2APIK3CA | |
| SCHEMBL16184191 | 0.88 | PDGFRB (0.39) | PIK3CACD38CHRNA7LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | NPC1 2208/4885PKM 2633/4885RAB9A 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.